[show abstract][hide abstract] ABSTRACT: Sarcolectin (SCL) is a nonspecific stimulator of cellular DNA synthesis that was found in all animal sera tested to date. It inhibits the established interferon (IFN)-dependent antiviral state, restoring cells to their normal status. In this study, we examined the excretion/secretion of the IFN antagonist SCL in sera from healthy donors and in sera collected during different periods of human immunodeficiency virus type 1 (HIV-1) infection. We followed HIV-1-infected patients during all stages of development (seroconversion, initial and advanced phases of AIDS) and found a significant increase in SCL in sera of HIV-infected patients compared with seronegative subjects used as controls. This increase was established during seroconversion, and then the titers leveled off. In the final stage of the disease, the SCL titer increased again very significantly. We attribute this rapid rise to the virus-dependent destruction of T cells that can no longer be repaired. The high SCL level observed at this final stage, which is most predictive of the disease's progression, suggests that the action, rather than the production, of IFN is impaired.
Journal of Interferon & Cytokine Research 04/2002; 22(3):305-10. · 3.30 Impact Factor
[show abstract][hide abstract] ABSTRACT: a a b b a The aim of this study was to investigate the involvement of sarcolectin in HIV-1 pathogenesis. During the infection and during progression of the disease the immune functions are indeed repeatedly challenged. We studied the presence of sarcolectin in three cohorts. Two were HIV-infected patients randomly selected at different phases of the disease as indicated: (a) controls; (b) seroconverted or early phase of AIDS (Centers for Disease Control and Prevention (CDC) I/II); (c) advanced AIDS (CDC III) generalized lymphadenopathy with or without common symptoms (CDC IV) opportunistic infections or secondary tumours were studied. Our results indicated that sarcolectin was overproduced in sera from AIDS patients compared with sera from control donors. Statistical calculations using regression coefficients showed a significant increase of sarcolectin titres in sera: between (a)/(b) t: 6,32; (a)/(c) t: 9,77; (b)/(c) t: 10,21. In all groups < 0.001(). Moreover, Western blotting assays showed that more sarcolectin was produced in sera in advanced cases of AIDS when compared with controls (results not shown). (6,7)